QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
NYSE:HAE

Haemonetics (HAE) Stock Price, News & Analysis

$74.77
+0.61 (+0.82%)
(As of 03/4/2024 ET)
Today's Range
$73.68
$74.98
50-Day Range
$71.25
$86.95
52-Week Range
$70.74
$95.26
Volume
281,333 shs
Average Volume
452,512 shs
Market Capitalization
$3.80 billion
P/E Ratio
30.39
Dividend Yield
N/A
Price Target
$104.67

Haemonetics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
40.0% Upside
$104.67 Price Target
Short Interest
Bearish
3.66% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.54
Upright™ Environmental Score
News Sentiment
1.01mentions of Haemonetics in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
7.09%
From $3.95 to $4.23 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.62 out of 5 stars

Medical Sector

87th out of 948 stocks

Surgical & Medical Instruments Industry

13th out of 96 stocks


HAE stock logo

About Haemonetics Stock (NYSE:HAE)

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

HAE Stock Price History

HAE Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Haemonetics Corp.
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Haemonetics: Fiscal Q3 Earnings Snapshot
Haemonetics Q3 2024 Earnings Preview
Haemonetics earnings: here's what Wall Street expects
HAE vs. ABT: Which Stock Is the Better Value Option?
3 Stocks to Buy for Consistent Sales Growth
See More Headlines
Receive HAE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Haemonetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/08/2024
Today
3/04/2024
Fiscal Year End
3/31/2024
Next Earnings (Estimated)
5/09/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
CUSIP
40502410
Employees
3,034
Year Founded
1971

Price Target and Rating

Average Stock Price Target
$104.67
High Stock Price Target
$115.00
Low Stock Price Target
$94.00
Potential Upside/Downside
+40.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$115.40 million
Pretax Margin
12.68%

Debt

Sales & Book Value

Annual Sales
$1.17 billion
Cash Flow
$5.00 per share
Book Value
$16.22 per share

Miscellaneous

Free Float
49,877,000
Market Cap
$3.79 billion
Optionable
Optionable
Beta
0.34

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report














HAE Stock Analysis - Frequently Asked Questions

Should I buy or sell Haemonetics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HAE shares.
View HAE analyst ratings
or view top-rated stocks.

What is Haemonetics' stock price target for 2024?

2 equities research analysts have issued 1 year price targets for Haemonetics' shares. Their HAE share price targets range from $94.00 to $115.00. On average, they predict the company's share price to reach $104.67 in the next year. This suggests a possible upside of 40.0% from the stock's current price.
View analysts price targets for HAE
or view top-rated stocks among Wall Street analysts.

How have HAE shares performed in 2024?

Haemonetics' stock was trading at $85.51 on January 1st, 2024. Since then, HAE stock has decreased by 12.6% and is now trading at $74.77.
View the best growth stocks for 2024 here
.

Are investors shorting Haemonetics?

Haemonetics saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 1,840,000 shares, an increase of 10.2% from the January 31st total of 1,670,000 shares. Based on an average daily trading volume, of 385,000 shares, the days-to-cover ratio is currently 4.8 days. Approximately 3.7% of the shares of the company are short sold.
View Haemonetics' Short Interest
.

When is Haemonetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our HAE earnings forecast
.

How were Haemonetics' earnings last quarter?

Haemonetics Co. (NYSE:HAE) posted its quarterly earnings data on Thursday, February, 8th. The medical instruments supplier reported $1.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.94 by $0.10. The medical instruments supplier earned $336.20 million during the quarter, compared to the consensus estimate of $320.84 million. Haemonetics had a trailing twelve-month return on equity of 22.37% and a net margin of 9.97%. The firm's revenue was up 10.1% on a year-over-year basis. During the same period in the prior year, the company earned $0.85 earnings per share.

What guidance has Haemonetics issued on next quarter's earnings?

Haemonetics issued an update on its FY24 earnings guidance on Thursday, February, 8th. The company provided earnings per share (EPS) guidance of $3.90-4.00 for the period, compared to the consensus earnings per share estimate of $3.89. The company issued revenue guidance of ~$1.28-1.31 billion, compared to the consensus revenue estimate of $1.27 billion.

What is Christopher Simon's approval rating as Haemonetics' CEO?

48 employees have rated Haemonetics Chief Executive Officer Christopher Simon on Glassdoor.com. Christopher Simon has an approval rating of 63% among the company's employees. This puts Christopher Simon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Haemonetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), AbbVie (ABBV), Citigroup (C), Align Technology (ALGN), Chipotle Mexican Grill (CMG), Netflix (NFLX) and Pfizer (PFE).

Who are Haemonetics' major shareholders?

Haemonetics' stock is owned by a number of institutional and retail investors. Top institutional investors include Capital Research Global Investors (12.84%), Vanguard Group Inc. (10.65%), Dimensional Fund Advisors LP (1.63%), Boston Trust Walden Corp (1.41%), Westfield Capital Management Co. LP (1.40%) and Fisher Asset Management LLC (1.40%). Insiders that own company stock include Anila Lingamneni, Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Laurie A Miller, Mark W Kroll, Mark W Kroll, Michelle L Basil, Michelle L Basil, Stewart W Strong and William P Mr Burke.
View institutional ownership trends
.

How do I buy shares of Haemonetics?

Shares of HAE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:HAE) was last updated on 3/4/2024 by MarketBeat.com Staff